Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edus H Warren

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Nature Communications|September 2, 2023
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myelomaDavid G Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
International Journal of Radiation Oncology, Biology, Physics|November 23, 2019
A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung CancerAngel Qin, Ramesh Rengan, Sylvia Lee, et al.
Blood|March 13, 2023
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphomaRyan C Lynch, Chaitra S Ujjani, Christina Poh, et al.
Blood|October 21, 2016
Replication of associations between genetic polymorphisms and chronic graft-versus-host diseasePaul J Martin, Wenhong Fan, Barry E Storer, et al.
Blood Advances|May 30, 2024
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responsesEdward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Nature Communications|September 2, 2023
Immunophenotypic correlates of sustained MRD negativity in patients with multiple myelomaDavid G Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
International Journal of Radiation Oncology, Biology, Physics|November 23, 2019
A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung CancerAngel Qin, Ramesh Rengan, Sylvia Lee, et al.
Blood|March 13, 2023
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphomaRyan C Lynch, Chaitra S Ujjani, Christina Poh, et al.
Blood|October 21, 2016
Replication of associations between genetic polymorphisms and chronic graft-versus-host diseasePaul J Martin, Wenhong Fan, Barry E Storer, et al.
Blood Advances|May 30, 2024
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responsesEdward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, et al.
Pageof 9